A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
Authors
McNamara, Mairéad GLe, L
Horgan, A
Aspinall, A
Burak, K
Dhani, N
Chen, E
Sinaei, M
Lo, G
Kim, T
Rogalla, P
Bathe, O
Knox, J
Affiliation
Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; The Christie NHS Foundation TrustIssue Date
2015-01-06
Metadata
Show full item recordAbstract
Second-line treatment options in advanced hepatocellular carcinoma (HCC) are limited. Axitinib, a selective potent tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor VEGF) receptors 1, 2, and 3, merits exploration in HCC.Citation
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. 2015: CancerJournal
CancerDOI
10.1002/cncr.29227PubMed ID
25565269Type
ArticleLanguage
enISSN
1097-0142ae974a485f413a2113503eed53cd6c53
10.1002/cncr.29227
Scopus Count
Collections
Related articles
- Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
- Authors: Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J
- Issue date: 2009 Aug 10
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
- Authors: Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ
- Issue date: 2011 Dec 3
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
- Authors: Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L
- Issue date: 2013 Nov
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
- Authors: Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI
- Issue date: 2013 May
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
- Authors: Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H, Japan Axitinib Phase II Study Group
- Issue date: 2011 Nov